ELI LILLY & Co is 157.3x more valuable than Protagonist Therapeutics, Inc by market capitalization ($1.070 T vs $6.80 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | PTGX | LLY |
|---|---|---|
| Market cap | $6.80 B | $1.070 T |
| US-listed rank | #1171 | #10 |
| Revenue (latest FY) | $46.02M | $65.18B |
| Net income (latest FY) | -$130.15M | $20.64B |
| Net margin | -282.8% | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 668 | 989 |
ELI LILLY & Co is 157.3x more valuable than Protagonist Therapeutics, Inc by market capitalization ($1.070 T vs $6.80 B).
In their latest fiscal years, Protagonist Therapeutics, Inc reported $46.02M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Protagonist Therapeutics, Inc and ELI LILLY & Co, or browse the full rankings.